Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARMOUR Residential REIT, Inc. (ARR) vs Danaher Corporation (DHR) Price & Performance

ARMOUR Residential REIT, Inc.
Danaher Corporation

Price performance

Price movement over the last 24 hours

Key statistics

ARMOUR Residential REIT, Inc. vs Danaher Corporation — how do they compare? ARMOUR Residential REIT, Inc. trades at $17.1 (market cap $2.11B), while Danaher Corporation trades at $199.4 (market cap $140.88B). The key difference: Danaher Corporation is far larger — about 66.8× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays the higher dividend (16.89%). Which is the better fit depends on your goals.

ARRDHR
Market Cap
$2.11B$140.88B
Sector
FinancialsHealth
52-Week High
$19.12$242.05
52-Week Low
$14.05$161.91
Dividend Yield
16.89%0.8%
Enterprise Value
$153.66B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARMOUR Residential REIT, Inc.

ARR trades at $17.05, down 0.23% today, with a neutral technical signal and bullish moving averages. The stock shows a low P/E of 6.85 and P/B of 0.9, indicating potential undervaluation, while recent earnings beat expectations in Q1 2026. Dividend payments remain steady at $0.24 per share, supporting income appeal. Revenue for 2025 was $332M with a net income margin of 97.2%, though cash flow trends show volatility in investing activities.

Outlook is mixed: analyst consensus is a $18.50 price target with 20% buy ratings, but risks include volatile earnings and high cash flow swings. The stock offers value and yield, yet requires caution due to operational inconsistencies and market sentiment leaning hold.

Danaher Corporation

Danaher (DHR) trades at $199.05, up 1.57% today, with strong technical momentum as price approaches resistance at $200. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.06 exceeding expectations of $1.94, though revenue growth remains modest at 2.9% year-over-year. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment, supporting positive analyst sentiment.

DHR presents a mixed outlook with strong analyst support (69% buy ratings) and a $214.73 consensus target offering 7.9% upside, but faces risks from elevated valuation (P/E 38.58) and slowing profit margins. The stock's near-term direction will depend on Q2 2026 earnings delivery and biotechnology segment performance amid competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARMOUR Residential REIT, Inc.

ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.

Read more on ARR

About Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

Read more on DHR